Eastern Canadian Colorectal Cancer Consensus Conference: Setting the Limits of Resectable Disease
Michael M. Vickers(Ottawa Hospital), Timothy R. Asmis(Ottawa Hospital), Rakesh Goel(Ottawa Hospital), Stéphane Barrette(Montreal General Hospital), Jamil Asselah(McGill University), Mohamed K. Hussein(Cape Breton Regional Hospital), James Biagi(Queen's University), Michael P. Thirlwell(McGill University Health Centre), Laura A. Dawson(Princess Margaret Cancer Centre), Stephen Welch(Cancer Care Ontario), Derek J. Jonker(University of Ottawa), Nazik Hammad(St. Michael's Hospital), R. Rajan(Montreal General Hospital), James Villeneuve(University of Ottawa), Mustapha Tehfé(Centre Hospitalier de l’Université de Montréal), M. Rother(Credit Valley Hospital), Geoff Porter(Canadian Partnership Against Cancer), Nirit Yarom(The King's College), Ronald L. Burkes(Mount Sinai Hospital), E. Chen(The King's College), Nancy Perrin(Oregon Health & Science University), Bruce Colwell, R. Létourneau(Montreal General Hospital), Neil R. Michaud(Epizyme (United States)), Benoît Samson(Hôpital Charles-Le Moyne), Jean A. Maroun(American Society of Clinical Oncology), S. El-Sayed(The King's College), D. Jalink(The King's College), Sudhir Sundaresan(University of Ottawa), C. Cripps(Canadian Partnership Against Cancer), P. Champion(Royal Marsden Hospital)
Cited by 22
Related Papers
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Cetuximab for the Treatment of Colorectal Cancer
|New England Journal of Medicine|2007|1.8k
American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
|Journal of Clinical Oncology|2004|1.5k